In final draft guidance published today we've confirmed that we’re unable to recommend cerliponase alfa (also called Brineura and made by BioMarin) for routine NHS use in treating neuronal ceroid lipofuscinosis type 2 (CLN2), a rare and life-limiting form of Batten disease.
UK NICE · August 14, 2025
NICE final guidance: cerliponase alfa (Brineura) not recommended for routine NHS use in CLN2 Batten disease
Original title: Final decision on cerliponase alfa for Batten disease treatment confirmed
NICE has issued final guidance declining to recommend cerliponase alfa for routine NHS treatment of neuronal ceroid lipofuscinosis type 2.
Published by UK NICE. HealthSignal links to the original document; the summary above is extracted from the source text.